Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
01 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hengruis-camrelizumab-combo-therapy-doubles-the-five--year-survival-of-patients-with-advanced-squamous-lung-cancer---a-potential--paradigm-shift-in-clinical-outcome-for-this-difficult-to-treat-population-302416809.html
29 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-enters-exclusive-license-with-hengrui-pharma-for-shr-4849-a-novel-phase-1-dll3-topo-i-payload-adc-targeting-sclc-and-net-solid-tumors-302339847.html
18 Jan 2020
// Angus Liu FIERCE PHARMA
https://www.fiercepharma.com/pharma-asia/hengrui-s-sun-piaoyang-china-s-richest-pharma-leader-sort-steps-down-after-30-year-run
11 Oct 2018
// Angus Liu FIERCE PHARMA
https://www.fiercepharma.com/pharma-asia/big-pharma-s-cancer-drugs-take-50-plus-discount-for-china-s-insurance-scheme
28 Feb 2018
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208234
03 Nov 2015
// FDA
https://www.pharmacompass.com/pdf/news/shanghai-hengruis-generic-sevoflurane-approved-in-us-for-anesthesia-1446812892.pdf
Details:
SHR-1210 (camrelizumab) is a IgG4 mAb developed by Hengrui, with high binding affinity to PD-1, being developed in various solid tumors, including lung, liver, esophageal, and nasopharyngeal cancer.
Lead Product(s): Camrelizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Brand Name: SHR-1210
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Camrelizumab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hengrui Combo Therapy Doubles Five-Year Survival in Advanced Lung Cancer
Details : SHR-1210 (camrelizumab) is a IgG4 mAb developed by Hengrui, with high binding affinity to PD-1, being developed in various solid tumors, including lung, liver, esophageal, and nasopharyngeal cancer.
Product Name : SHR-1210
Product Type : Antibody
Upfront Cash : Inapplicable
April 01, 2025
Regulatory Info : RX
Registration Country : USA
Shanghai Hengrui Pharmaceutical
Dosage Form : LIQUID;INHALATION
Brand Name : DESFLURANE
Dosage Strength : 100%
Packaging :
Approval Date : 2018-02-26
Application Number : 208234
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Shanghai Hengrui Pharmaceutical
Dosage Form : LIQUID;INHALATION
Brand Name : SEVOFLURANE
Dosage Strength : 100%
Packaging :
Approval Date : 2015-11-03
Application Number : 203793
Regulatory Info : RX
Registration Country : USA
RLD : No
TE Code : AN
Shanghai Hengrui Pharmaceutical
Dosage Form : LIQUID; INHALATION
Proprietary Name : DESFLURANE
Dosage Strength : 100%
Approval Date : 2018-02-26
Application Number : 208234
RX/OTC/DISCN : RX
RLD : No
TE Code : AN
RLD : No
TE Code : AN
Shanghai Hengrui Pharmaceutical
Dosage Form : LIQUID; INHALATION
Proprietary Name : SEVOFLURANE
Dosage Strength : 100%
Approval Date : 2015-11-03
Application Number : 203793
RX/OTC/DISCN : RX
RLD : No
TE Code : AN
Inspections and registrations
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-03-27
Shanghai Hengrui Pharmaceutical
City : Shanghai
State :
Country/Area : CN
Zip :
District : ORA
Center : CDER
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-03-27
District Decision : Voluntary Action Indicated
Inspection End Date : 2013-09-06
Shanghai Hengrui Pharmaceutical
City : Shanghai
State :
Country/Area : CN
Zip :
District : ORA
Center : CDER
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2013-09-06
Shanghai Hengrui Pharmaceutical
Type : GMP Certificates
Number : NL/H 13/011...
EudraGMDP Key : 17752
Country : China
Issue Date :
Post Code : 200245
NCA Ref : 1.7752137769...
City : Shanghai
API Manufacturer :
FDF Manufacturer : FDF MANUFACTURE
Facility Name : Shanghai Hengrui Pharmaceutica...
Business Address : 279 Wenjing Road Minhang Dis...
FEI Number : 3003910445
Country : China
Paid in : 2019
ABOUT THIS PAGE